ArticleEClinicalMedicine2019
A Whole-genome Sequencing Analysis of
Article in EClinicalMedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 62 citations in OpenAlex.
- Rapid expansion of penA allele 60.001-containing endemic ceftriaxone-resistant gonococcal ST8123 lineage in Hangzhou, China.Infection · 2026Article
- Article
- Stepwise evolution and clonal enrichment of gepotidacin resistance inAntimicrobial agents and chemotherapy · 2026Article
- In Vitro Activity of Zoliflodacin AgainstAntibiotics (Basel, Switzerland) · 2026Article
- Resistance Mechanisms and Molecular Epidemiology of Neisseria gonorrhoeae with Low Susceptibility/Resistance to Azithromycin or Cephalosporins.Infection and drug resistance · 2026Article
- Whole-genome characterization of seven multidrug-resistantFrontiers in microbiology · 2026Article
- Emergence, evolution and temporal spread of ceftriaxone-resistantEmerging microbes & infections · 2025Article
- Emerging epidemic of the Africa-type plasmid in penicillinase-producingEmerging microbes & infections · 2025Article
- Molecular screening to track ceftriaxone-resistant FC428-likeEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Advances in genotypic antimicrobialresistance testing: a comprehensive review.Science China. Life sciences · 2025Review
- Antimicrobial treatment and resistance in sexually transmitted bacterial infections.Nature reviews. Microbiology · 2024Review
- Identification of ceftriaxone-resistant Neisseria gonorrhoeae FC428 clone and isolates harboring a novel mosaic penA gene in Chengdu in 2019-2020.Annals of clinical microbiology and antimicrobials · 2023Article
- Themisto: a scalable colored k-mer index for sensitive pseudoalignment against hundreds of thousands of bacterial genomes.Bioinformatics (Oxford, England) · 2023Article
- Dissemination of Neisseria gonorrhoeae with decreased susceptibility to extended-spectrum cephalosporins in Southern China, 2021: a genome-wide surveillance from 20 cities.Annals of clinical microbiology and antimicrobials · 2023Article
- Machine learning models for Neisseria gonorrhoeae antimicrobial susceptibility tests.Annals of the New York Academy of Sciences · 2023Review
- Whole-Genome Sequencing of Neisseria gonorrhoeae Isolates with Antimicrobial Resistance Plasmids from a Homeless Community in Colombia.Microbiology resource announcements · 2022Article
- Whole Genome Analyses Accurately IdentifyInternational journal of molecular sciences · 2022Article
- Reliability of Genetic Alterations in Predicting Ceftriaxone Resistance in Neisseria gonorrhoeae Globally.Microbiology spectrum · 2022Article
- Bioinformatics tools used for whole-genome sequencing analysis of Neisseria gonorrhoeae: a literature review.Briefings in functional genomics · 2022Review
- A Multiplex Molecular Assay for Detection of SixAntimicrobial agents and chemotherapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTracking the spread of the
methodsWe obtained clinical isolates and data from the China Gonococcal Resistance Surveillance Programme (China-GRSP) from 2012 to 2013. We sequenced the genomes of 435 clinical isolates of
findingsThe most prevalent MLST STs in our gonococcal population were MLST ST7827 (n = 74), followed by ST7365 (n = 58), ST1600 (n = 38), ST7367 (n = 35), and ST7363 (n = 29). MLST ST1901 which was reported as the predominant ST in the US was not found in our population. A total of 2512 strains, including additional 2077 published NG strains, were further included for phylogenetic analysis. It generated two distinct lineages - lineage 1 and lineage 2. Analysis of MLST ST1901 in the database indicate that most of MLST ST1901 isolates in the lineage2.6 were Cfx-DS isolates while all isolates in the lineage 2.1 were sensitive to ceftriaxone (77/110 vs. 0/13; p < 0.001). ST1901/lineage 2.6 is a ceftriaxone resistant clone which cannot distinguished by MLST genotyping. In the isolates from our study, the MICs of ceftriaxone for ST7363/lineage 2.6 isolates ranged from 0.008-0.125 mg/L (mean ± SD; 0.054 ± 0.043 mg/L) while those for ST7363/lineage 2.8 isolates ranged from 0.032-0.250 mg/L (0.134 ± 0.085 mg/L). All ST7363/lineage 2.8 isolates contained
interpretationTo our knowledge, current study is the first WGS-based analysis of gonococcal population at national level in Asia. China harbors the different predominant clones associated with decreased susceptibility to ceftriaxone from those clones circulated in other regions. The findings from the study can be not only used as baseline data for future studies in China but also contributable to our understanding on spread of
fundingThe Chinese Academy Medical Sciences (CAMS) Initiative for Innovative Medicine.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.